There were 2,163 press releases posted in the last 24 hours and 405,792 in the last 365 days.

On The Radar: Ohr Pharmaceutical

September 2, 2010 (FinancialWire) (Investrend Information Syndicate) (Go to http://www.financialwire.net/?s=ftrdnwswnd for all of today’s featured news.) — Healthcare/Biotech company Ohr Pharmaceutical, Inc. (OHRP.OB) (Approx. Market Cap: US$ 9.6 Million) stock closed at $0.27 yesterday on volume of 300 shares, compared to its $0.49 close on June 23, 2010, on volume of 4,500 shares (50 trading sessions ago). OHRP’s 50 day average adjusted close is $0.32. In terms of liquidity, OHRP’s 50-day average daily trading volume is 2,526 shares, with days ranging from zero shares traded to 38,300 shares traded during that 50-day period.

In the last fifty trading sessions OHRP stock has traded as high as $0.50 (intra-day) and as low as $0.15 (intra-day).

Business Week notes OHRP stock’s 52-week high as $1.25 on December 8, 2009, and its 52-week low as $0.14 on September 23, 2009.

Ohr Pharmaceutical engages in the development of drugs for underserved therapeutic needs. The company is developing OHR/AVR118 for the treatment of cachexia, a condition of physical wasting with loss of weight, fat, and lean muscle mass seen in patients with advanced cancer, AIDS, or other chronic and progressive diseases. Ohr is also developing EVIZON for the treatment of wet-AMD, a cause of severe vision loss in people over age 50. The company is based in Salt Lake City, Utah.

Recent OHRP quarterly financials are posted in FinancialWire(tm)’s reference section (at http://www.financialwire.net/2010/09/02/ohrp-qrtrly-financials/), and all of Ohr Pharmaceutical’s EDGAR filings are accessible via the SEC website (at http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001173281).

Lead-ins to press releases issued by OHRP since are provided below, and all press releases are accessible via the company’s website (at http://www.ohrpharmaceutical.net/).

04/12/10 – Ohr Pharmaceutical, Inc., announced today that Dr. Irach B. Taraporewala, B.S., M.S., Ph.D., a veteran healthcare executive with lengthy experience in drug development and regulatory strategy, was named chief executive officer, effective immediately.

04/20/10 – Ohr Pharmaceutical, Inc., announced today that it has established its headquarters in New York City. The company was previously based in Salt Lake City on an interim basis. "We are actively developing two later-stage drugs and need a convenient and accessible base of operations closer to our scientists," said chief executive officer Dr. Irach B. Taraporewala. "We look forward to communicating with investors and the biotech community as we progress throughout the clinical trial and commercialization stages."

04/27/10 – Ohr Pharmaceutical, Inc., announced that it has been awarded a new Japanese patent (#4441769) that includes claims related to a method of synthesis for Squalamine, Trodusquemine and related aminosterols, which is used in the development of the company's EVIZON(tm) therapeutic agent for the treatment of Wet-AMD, among other compounds. The patent is titled "Stereoselective Synthesis of 24-Hydroxylated Compounds Useful for the Preparation of Aminosterols, Vitamin D Analogs, and Other Compounds." Ohr was previously granted U.S. and Canadian patent protection for this intellectual property.

06/02/10 – Ohr Pharmaceutical, Inc., today announced that it has been awarded a new U.S. patent (#7,728,157) that includes claims related to a method of synthesis used in the development of the company's EVIZON(tm) therapeutic agent for the treatment of Wet-AMD, among other compounds. The patent is titled "Regioselective and Stereoselective Oxidation of Fused Ring Systems Useful for the Preparation of Aminosterols." This is the first patent issued for this intellectual property and it expires in 2023.

8/13/10 — The company’s quarterly report (for the period ending 6/30/10) was issued.

8/19/10 — EDGAR Online quarterly financials posted. (Also posted at http://www.financialwire.net/2010/09/02/ohrp-qrtrly-financials/) All filings accessible via the SEC website (at http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001173281).

Financialwire(tm)’s “On The Radar” news beat features fundamentals-supported articles about lesser-capitalized public companies that are newly-listed and/or are making efforts toward being recognized. FinancialWire(tm)’s primary criteria for presenting these news articles includes avoiding hyperbole and including references to material information, in order to better serve shareholders and investors. FinancialWire(tm) is not compensated in any way by subject companies and/or any representatives of subject companies.

=========

Equity research on any public company is available through the Shareholders Research Alliance (go to http://www.investrend.com/synd0004 for more information).  Real-time, streaming research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate (at http://investrend.stocksmart.com/ss/html/hpcompany.html).  Current valuation analysis research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate (at http://www.valuengine.com/rep/searchsrep?pid=42&srchfor=).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public other companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation from subject entities, companies, equities, or representatives thereof, for its news, opinions or distributions. Further disclosure is posted at the FinancialWire(tm) website (at http://www.financialwire.net/disclosures.php and http://www.financialwire.net/2010/04/23/safe-harbor/). Additional resources for investors are also accessible via the FinancialWire(tm) website (at http://www.financialwire.net/2010/04/23/investor-resources/). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Copyright © MMX, FinancialWire(tm); All rights reserved.

[ssryrsyr] [nthrdrdrht] [otrchflupasst] [crsnglmn] [ftrdnwswnd] [wtchr] [stkev] [hlthcrdp] [biomedphrm]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.